STOCK TITAN

Cardio Diagnostics Holdings Inc SEC Filings

CDIO NASDAQ

Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Cardio Diagnostics Holdings Inc’s SEC reports aren’t just numbers—they contain clinical-trial updates, FDA pathway disclosures, and patent strategies tied to its AI-powered Genetic-Epigenetic Engine. If you have ever typed “Where can I find the Cardio Diagnostics quarterly earnings report 10-Q filing?” or hunted through 200 pages for risk factors, you know the challenge.

Our platform turns that complexity into clarity. Stock Titan’s AI reads every exhibit as soon as it lands on EDGAR, generating plain-English summaries so Cardio Diagnostics SEC filings are explained simply. You’ll receive real-time alerts the moment Cardio Diagnostics Form 4 insider transactions hit the wire—critical when executives trade after promising data. Need the full story behind an 8-K? We deliver Cardio Diagnostics 8-K material events explained in minutes, alongside keyword-searchable PDFs.

Here’s how professionals use this page:

  • Track Cardio Diagnostics insider trading Form 4 transactions or any executive stock transactions Form 4 without refreshing EDGAR.
  • Compare revenue trends and R&D spend with AI-backed Cardio Diagnostics earnings report filing analysis from each 10-Q.
  • Skim a Cardio Diagnostics annual report 10-K simplified to spot cash-burn rates and patent portfolio changes.
  • Review the latest Cardio Diagnostics proxy statement executive compensation to understand incentive alignment.

Whether you’re a fund manager monitoring pipeline milestones or a physician-investor understanding Cardio Diagnostics SEC documents with AI, you’ll find every filing type—10-K, 10-Q, 8-K, S-1, and more—updated in real time and distilled into actionable insight.

Rhea-AI Summary

Cardio Diagnostics Holdings Inc. (CDIO) – Form 4 insider filing

Director Peter K. Fung reported the grant of 1,736 stock options on 06/30/2025. Each option carries an exercise price of $3.60 and will expire on 06/30/2035. The filing indicates the transaction code “A,” denoting an acquisition rather than a sale. After this award, Fung directly holds 2,443 derivative securities (stock options) linked to CDIO common stock. No open-market purchases or disposals of common shares were disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

LogicMark, Inc. (LGMK) – Form 4 insider transaction dated 07/01/2025

Director Robert A. Curtis reported the grant of 2,500,000 stock options under Table II. The options:

  • Exercise/Conversion Price: $0.004 per share (effectively near-zero cost).
  • Date Exercisable: immediate on 07/01/2025.
  • Expiration: 06/30/2035 (10-year term).
  • Underlying security: common stock, one share per option.

The filing states the award was received as quarterly compensation for board service for the period ended 06/30/2025. After the transaction, Curtis beneficially owns 2.5 million derivative securities, held directly. No non-derivative share holdings were disclosed.

The Form 4 contains no sales, open-market purchases, or other equity movements, and no additional reporting persons.

Key takeaways for investors:

  • The option strike price is far below LGMK’s recent trading range, implying high intrinsic value if exercised and potential dilution if converted.
  • The grant strengthens director equity alignment, but shareholders should monitor aggregate option overhang and possible future exercises.
  • With only a single insider involved and no cash transaction, the immediate financial impact is limited; materiality depends on LogicMark’s total share count, which is not provided in the filing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Snowflake Inc. (SNOW) – Form 4 insider transaction

President of Products and Director Benoit Dageville reported an option exercise and coincident share sale on 06/30/2025:

  • Option exercise (Code M): 25,000 Class A shares acquired at an exercise price of $0.74, costing roughly $18.5 k.
  • Open-market sale (Code S): 25,000 Class A shares sold at an average price of $224.84, generating about $5.6 m gross proceeds.
  • Direct ownership decreased to 58,325 shares from 83,325 after the paired transactions.
  • The option exercised was fully vested and expires 02/07/2027; 419,863 options remain outstanding.

The trades were executed under a 10b5-1 trading plan adopted on 03/28/2025, providing pre-arranged execution and reducing the likelihood of information-based timing concerns.

Dageville continues to have large indirect stakes held in several trusts—two GRATs of 750,000 shares each and the Snow Trust holding 3,191,555 shares—although he disclaims beneficial ownership of one GRAT.

While the $5.6 m sale is relatively small versus total indirect holdings (~4.7 m shares) and was plan-driven, it trims direct exposure by roughly 30% and can be interpreted by some investors as modestly negative insider sentiment. No company-level financials or operational updates are contained in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Foot Locker, Inc. (FL) Form 4 filing: Director John Venhuizen reported the receipt of 3,364 shares of common stock on 07/01/2025. The shares represent the equity portion of his FY-2025 board retainer and were valued at $24.50 per share, the 06/30/2025 closing price. After the distribution, Venhuizen directly owns 6,915 FL shares. No derivative securities were involved and the transaction was coded “A” (grant/acquisition) rather than an open-market purchase. The filing is routine compensation-related and does not reflect a discretionary buy or sell decision.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Cardio Diagnostics Holdings (CDIO)?

The current stock price of Cardio Diagnostics Holdings (CDIO) is $3.8 as of July 3, 2025.

What is the market cap of Cardio Diagnostics Holdings (CDIO)?

The market cap of Cardio Diagnostics Holdings (CDIO) is approximately 5.7M.

What is the core technology behind Cardio Diagnostics Holdings Inc?

The company utilizes a proprietary artificial intelligence-driven integrated Genetic-Epigenetic Engine to evaluate cardiovascular risk factors. This technology combines genetic and epigenetic data to provide a more comprehensive risk assessment.

How does Cardio Diagnostics generate revenue?

Cardio Diagnostics focuses on the commercialization and licensing of its innovative diagnostic technology. Its revenue model is built around delivering a scalable solution that enhances early detection and personalized risk assessment in cardiovascular healthcare.

What makes Cardio Diagnostics unique in the cardiovascular diagnostics market?

Its unique integration of AI with combined genetic and epigenetic analysis sets it apart. This data-driven approach allows for individualized diagnostics, creating a more precise and personalized assessment of cardiovascular risk.

How does the company contribute to early detection of cardiovascular disease?

By harnessing advanced artificial intelligence algorithms, the company analyzes complex biological markers to identify early stages of cardiovascular risk. This early detection capability supports more timely interventions and informed treatment decisions.

What are the primary challenges faced by Cardio Diagnostics?

The company navigates challenges such as stringent regulatory environments and the need for continuous clinical validation. Additionally, it must stay abreast of rapid advancements in AI and data analytics technologies while ensuring its product remains reliable and accurate.

Who are the likely customers for Cardio Diagnostics' technology?

The primary customers include healthcare providers, research institutions, and diagnostic laboratories interested in personalized cardiovascular risk assessments. The technology is also of interest to academic research centers focused on precision medicine.

How does Cardio Diagnostics maintain its competitive edge?

The company continuously invests in research and development to improve its AI-driven diagnostic capabilities. Its focus on a personalized, data-driven approach to cardiovascular risk assessment differentiates it in a competitive landscape.

Is the technology developed by Cardio Diagnostics applicable to other healthcare areas?

While the primary emphasis is on cardiovascular diagnostics, the underlying technology has potential applications in related areas of personalized medicine. Its core methodology of integrating genetic and epigenetic data can be adapted to other diagnostic and predictive healthcare solutions.
Cardio Diagnostics Holdings Inc

NASDAQ:CDIO

CDIO Rankings

CDIO Stock Data

5.74M
1.61M
7.69%
4.93%
3.8%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CHICAGO